Oriola
The answer first
Does Oriola beat the market?
No, Oriola has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 11% of Nordic stocks
- Quality3
- Value64
- Trend18
No. 162 of 195 in healthcare
Expectations in the price
Moderate expectations
For the share to return about 9% a year from today's price, the cash Oriola keeps must grow about 3% a year for 10 years.
Max for seven days
Follow Oriola with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Oriola
Your first answer is free, no account needed.
Do you own Oriola, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Oriola and a few more. Free, no card.
Super Stock+44.6%In short
- Oriola has fallen 29.3% over the past year, including dividends.
- Overall, Oriola ranks better than 11% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 56.6%. The price is 75.5% below its peak now.
What do analysts think of Oriola?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 11% of Nordic stocks.
No. 162 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 194 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.90
- Asset turnoverSales divided by everything the company owns0.85
- Return on equityProfit divided by equity−21.0%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 24 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.5
- P/SPrice divided by sales0.2
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flow7.3
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 132 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−15.1%
- 6 months−17.1%
- 9 months−31.1%
- 12 months−29.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Oriola
One fund we follow owns Oriola. The share is how much of the fund the stock makes up.
- Norway1
From the funds' latest known holdings.
About Oriola
Oriola is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 800 employees.
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services.


See the full analysis of Oriola.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card